SWT21 Antibody

What is SWT21 Antibody and what organism does it target?

SWT21 Antibody (Product Code: CSB-PA412229XA01STA) is a polyclonal antibody raised in rabbits that specifically targets the SWT21 protein in Saccharomyces cerevisiae (strain YJM789), commonly known as Baker's yeast. This antibody has been developed through immunization with recombinant SWT21 protein and is purified using antigen affinity methods. The antibody is non-conjugated, supplied in liquid form, and has a Uniprot reference number of A6ZRQ0 . The antibody is designed exclusively for research applications and should not be used for diagnostic or therapeutic purposes.

What are the primary research applications for SWT21 Antibody?

SWT21 Antibody has been validated for specific research techniques including Enzyme-Linked Immunosorbent Assay (ELISA) and Western Blotting (WB). When used in Western blotting, the antibody can help identify and characterize the SWT21 protein by binding to its specific epitopes . These applications make it valuable for studying protein expression, localization, and interaction patterns in yeast models. Like other research antibodies, its utility extends to investigating protein modifications, but researchers should validate specificity for their particular experimental conditions, as antibody performance can vary significantly between applications .

What are the optimal storage conditions for SWT21 Antibody?

For optimal preservation of SWT21 Antibody activity, the recommended storage temperature is either -20°C or -80°C upon receipt. It's important to avoid repeated freeze-thaw cycles as these can compromise antibody integrity and functionality. The antibody is supplied in a storage buffer containing 0.03% Proclin 300 as a preservative and 50% Glycerol in 0.01M PBS at pH 7.4 . This buffer composition helps maintain stability during storage. When handling the antibody, it's advisable to aliquot it into smaller volumes to minimize exposure to repeated temperature changes, which is a standard practice for preserving antibody function across multiple experiments.

How should I validate SWT21 Antibody specificity before proceeding with experimental research?

Validating antibody specificity is a critical preliminary step in any research protocol using SWT21 Antibody. Begin with a titration experiment testing concentrations between 0.1-10 μg/ml to determine optimal antibody dilution for your specific application. Include both positive controls (samples known to express SWT21) and negative controls (samples where SWT21 is absent or knockdown/knockout samples) to confirm specificity .

For Western blotting validation, consider the following protocol:

• Run wild-type yeast lysate alongside SWT21 knockdown/knockout samples

• Test multiple blocking conditions (3-5% BSA vs. 5% non-fat milk)

• Include both reducing and non-reducing conditions

• Compare results with a second antibody targeting SWT21 (if available)

Validation is particularly important since research has demonstrated significant variability among commercially available antibodies, with different antibodies targeting the same protein often yielding contradictory results in identical experimental conditions .

What Western blotting protocol optimizations are recommended for SWT21 Antibody?

When performing Western blotting with SWT21 Antibody, several protocol optimizations can enhance specificity and reduce background interference:

Current research emphasizes that Western blot buffer composition and antibody concentration significantly influence results, highlighting the need for standardized reporting of experimental conditions . When publishing research using SWT21 Antibody, adhere to the Western Blotting Minimal Reporting Standard (WBMRS), which recommends comprehensive documentation of experimental parameters to improve reproducibility.

How can SWT21 Antibody be used to study protein-protein interactions in yeast models?

For investigating protein-protein interactions involving SWT21 in yeast, consider implementing co-immunoprecipitation (Co-IP) protocols optimized for yeast cells:

• Prepare yeast lysate under non-denaturing conditions using glass bead disruption in a buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.5% NP-40, and protease inhibitors

• Pre-clear lysate with protein A/G beads (1 hour at 4°C)

• Incubate pre-cleared lysate with SWT21 Antibody (5 μg per 1 mg of total protein) overnight at 4°C

• Add protein A/G beads and incubate for 3 hours at 4°C

• Wash beads 5 times with cold IP buffer

• Elute bound proteins and analyze by SDS-PAGE followed by Western blotting for potential interacting partners

This approach draws on principles similar to those used in current antibody research focused on structure-based design . When interpreting Co-IP results, consider validating key interactions using complementary methods such as yeast two-hybrid assays to strengthen your findings.

How does SWT21 Antibody performance compare in different species or strains of yeast?

SWT21 Antibody is specifically generated against and validated for Saccharomyces cerevisiae strain YJM789 . When using this antibody with other yeast strains or species, cross-reactivity assessment is essential, as epitope conservation may vary. If working with other strains or related yeast species, consider:

• Performing sequence alignment analysis of the SWT21 protein across different strains to predict potential cross-reactivity

• Testing antibody recognition using recombinant SWT21 proteins from different strains

• Validating with Western blotting across multiple strains, comparing band patterns and intensities

Recent antibody research has demonstrated that even slight variations in target epitopes can significantly impact binding specificity . When working with non-validated strains, include comprehensive controls and consider developing strain-specific validation protocols to ensure accurate interpretation of your results.

What are the most common causes of false positives or background issues when using SWT21 Antibody?

When encountering high background or false positive signals with SWT21 Antibody, consider these common causes and solutions:

Research on antibody reliability has shown that experimental variability is a significant concern, with factors such as buffer composition and antibody concentration greatly influencing Western blot results . Implementing consistent protocols and meticulous documentation of experimental conditions can help mitigate these issues.

How can I troubleshoot weak or absent signals when using SWT21 Antibody?

When facing weak or absent signals with SWT21 Antibody, implement this systematic troubleshooting approach:

• Verify target protein expression and sample preparation:

  • Confirm SWT21 expression in your yeast strain using RT-PCR

  • Ensure complete cell lysis and protein extraction

  • Check protein degradation with Ponceau S staining

• Optimize antibody conditions:

  • Reduce antibody dilution (use more concentrated antibody)

  • Extend primary antibody incubation (overnight at 4°C)

  • Test different blocking agents (BSA vs. milk)

• Enhance detection sensitivity:

  • Use a more sensitive detection system (e.g., enhanced chemiluminescence)

  • Extend film exposure time or increase imaging duration

  • Consider signal amplification methods (e.g., biotin-streptavidin system)

• Address technical factors:

  • Verify transfer efficiency with reversible staining

  • Optimize protein loading (10-30 μg total protein per lane)

  • Test membrane with different pore sizes (0.2 μm vs. 0.45 μm)

Research indicates that antibody performance can vary significantly between applications and experimental conditions, emphasizing the importance of optimization for each specific research context .

How does immunodetection with SWT21 Antibody compare to genetic tagging approaches?

Comparing immunodetection with SWT21 Antibody to genetic tagging approaches presents important considerations for experimental design:

What are the advantages and limitations of SWT21 Antibody compared to mass spectrometry for protein detection?

Understanding the comparative strengths and limitations of antibody-based detection versus mass spectrometry helps researchers select the most appropriate method for their specific research questions:

While SWT21 Antibody excels in specific detection of its target protein in applications like Western blotting and ELISA, mass spectrometry offers broader protein identification capabilities and can reveal unexpected modifications or interactions . Consider integrating both approaches for comprehensive protein characterization, using antibody-based methods for targeted validation of mass spectrometry findings.

How might advanced antibody engineering techniques improve future versions of SWT21 Antibody?

Recent advances in antibody engineering present opportunities for developing enhanced versions of SWT21 Antibody with improved specificity and versatility:

• Nanobody Development: Camelid-derived single-domain antibodies (nanobodies) similar to those used in HIV research could offer advantages for SWT21 detection, including smaller size for accessing restricted epitopes and greater stability . These nanobodies can be engineered into multi-specific formats targeting different regions of SWT21 simultaneously.

• Structure-Based Engineering: Computational modeling approaches that predict antibody-antigen interactions could be applied to redesign SWT21 Antibody with enhanced specificity . This approach involves:

  • 3D structure prediction of SWT21 protein epitopes

  • In silico antibody design targeting specific binding pockets

  • Directed evolution to optimize binding kinetics

• Multi-functional Antibody Formats: Following the "3-in-1 design" concept described in cancer antibody research, future SWT21 antibodies could combine multiple functions :

  • Primary detection of SWT21 protein

  • Secondary binding to fluorescent reporters for direct visualization

  • Tertiary binding to affinity tags for simplified purification

These engineering approaches could substantially enhance the performance of SWT21 Antibody in research applications, potentially offering higher specificity, improved signal-to-noise ratios, and expanded functionality across multiple experimental platforms.

What emerging research techniques might leverage SWT21 Antibody in new ways?

Emerging research technologies present novel applications for SWT21 Antibody beyond traditional methods:

• Spatial Transcriptomics Integration: Combining SWT21 Antibody immunodetection with spatial transcriptomics could correlate protein localization with gene expression patterns in yeast colonies:

  • Perform sequential immunofluorescence with SWT21 Antibody

  • Capture spatial gene expression data from the same sample

  • Integrate datasets to correlate protein presence with transcriptional activity

• Microfluidic Single-Cell Analysis: Adapting SWT21 Antibody for microfluidic platforms enables analysis of protein expression heterogeneity across yeast populations:

  • Encapsulate individual yeast cells in droplets

  • Perform in-droplet cell lysis and antibody staining

  • Analyze thousands of cells for SWT21 expression variance

• CRISPR-Antibody Hybrid Techniques: Combining CRISPR technology with SWT21 Antibody could enable targeted protein modification studies:

  • Use CRISPR-Cas9 to introduce specific mutations in SWT21

  • Apply SWT21 Antibody to assess effects on protein expression and localization

  • Develop CRISPR activation/repression systems regulated by antibody detection

These emerging applications represent the frontier of antibody-based research techniques, potentially transforming how SWT21 Antibody can be utilized in yeast biology research and expanding its utility beyond conventional detection methods.